Maravai LifeSciences Appoints Trey Martin to Board of Directors
July 29 2024 - 4:05PM
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of
life science reagents and services to researchers and biotech
innovators, announced that its CEO William “Trey” Martin, III has
been appointed to the Company’s Board of Directors, effective July
31, 2024. This strategic appointment underscores Martin’s
commitment to innovation, leadership capabilities, and deep
industry knowledge.
“We are thrilled to welcome Trey to our Board of Directors,”
said Carl Hull, Maravai’s co-founder and Executive Chair of its
Board of Directors. “Trey’s extensive experience and depth of
knowledge will bring valuable perspectives and enrich our
collective decision-making. His close connection to our markets,
customers, and employees will undoubtedly enhance our ability to
navigate emergent risks and seize opportunities. Trey’s presence
reinforces the bridge between our Board and our day-to-day
operations, ensuring we remain deeply connected and responsive to
the issues that matter most. Since his assumption of the CEO role
last year, the Board has been impressed with his leadership
capabilities and we believe his contributions to our Board will
help Maravai deliver on our return to growth strategy and achieve
our ambitious objectives.”
“I am honored to join Maravai’s Board of Directors and will
continue to work closely with our exceptional team,” Martin said.
“I remain confident in the fundamental strength of our end markets,
and the value we provide our customers for the life-changing
development of drug therapies, diagnostics and novel vaccines.
Together with the Board, I am committed to building a strong
foundation for long-term, sustainable growth of our
businesses.”
Mr. Martin has more than 25 years of executive leadership
experience in life sciences operations, engineering, sales, product
development and marketing. Since July 2023, he has served as
Maravai’s Chief Executive Officer. From December 2022 to July 2023,
Mr. Martin served as President, Biologics Safety Testing at
Maravai. Prior to that, he was Senior Vice President, Genomic
Medicines, at Danaher Corporation. Mr. Martin originally joined
Danaher with the acquisition of Integrated DNA Technologies (IDT)
in 2018 and served as President of the IDT business there for over
three years. Prior to its acquisition, Mr. Martin held positions of
increasing responsibility over more than two decades at IDT, and
contributed to the consistent growth and competitiveness of the
company’s genomic solutions business through organic and inorganic
growth investments. Mr. Martin holds a Bachelor’s in biochemistry
from the University of Iowa.
Martin joins Maravai Executive Chair Carl Hull, as one of two
executives on the Company’s Board.
Martin has been appointed to fill the vacancy on the Board that
will be created by Anat Ashkenazi’s previously-disclosed
resignation.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
and novel vaccines and to support research on human diseases.
Maravai’s companies are leaders in providing products and services
in the fields of nucleic acid synthesis and biologics safety
testing to many of the world’s leading biopharmaceutical, vaccine,
diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit
www.maravai.com.
Forward-looking StatementsThis press release
may contain "forward-looking statements" within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Investors are cautioned that statements in this
press release which are not strictly historical statements
constitute forward-looking statements, including, without
limitation, statements related to the expectation that Mr. Martin
will drive Maravai’s growth strategy and objectives, constitute
forward-looking statements identified by words like “plan,” “will,”
“expect,” “believe,” “may,” “anticipate,” or “could” and similar
expressions. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation, continued demand for our COVID-19 related products and
services, which currently comprise a significant portion of our
revenue, and the other risks and uncertainties described in greater
detail in the “Risk Factors” section of our most recent Annual
Report on Form 10-K and other filings with the U.S. Securities and
Exchange Commission. Actual results may differ materially from
those contemplated by these forward-looking statements, and
therefore you should not rely upon them. These forward-looking
statements reflect our current views and we do not undertake to
update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date
hereof except as required by law.
Contact Information:
Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Sep 2023 to Sep 2024